| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/29/2011 | US20110236421 Flavivirus host range mutations and uses thereof |
| 09/29/2011 | US20110236420 Bluetongue virus recombinant vaccines and uses thereof |
| 09/29/2011 | US20110236419 Recombinant cdv compositions and uses thereof |
| 09/29/2011 | US20110236418 Materials and Methods for Improved Vaccination |
| 09/29/2011 | US20110236417 Vaccines comprising mutant attenuated influenza viruses |
| 09/29/2011 | US20110236416 Foot and mouth disease virus recombinant vaccines and uses thereof |
| 09/29/2011 | US20110236415 Virulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| 09/29/2011 | US20110236414 Bacterial Polysaccharide-Polypeptide Conjugate Compositions |
| 09/29/2011 | US20110236412 Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| 09/29/2011 | US20110236410 Klebsiella antigens |
| 09/29/2011 | US20110236409 Overlapping peptides from variable antigens, t cell populations and uses thereof |
| 09/29/2011 | US20110236408 Respiratory synctial virus (rsv) sequences for protein expression and vaccines |
| 09/29/2011 | US20110236407 Vaccine for runting-stunting syndrome |
| 09/29/2011 | US20110236406 Immunogenic compositions comprising hmgb1 polypeptides |
| 09/29/2011 | US20110236400 Tetrahydropyranochromene gamma secretase inhibitors |
| 09/29/2011 | US20110236399 Compositions and methods for prophylactic and therapeutic treatment of infection |
| 09/29/2011 | US20110236398 Antibody Formulation |
| 09/29/2011 | US20110236397 Limited proteolysis of cd2ap and progression of renal disease |
| 09/29/2011 | US20110236380 Ligands that bind il-13 |
| 09/29/2011 | US20110236376 Non-neutralizing immunity to influenza to prevent secondary bacterial pneumonia |
| 09/29/2011 | US20110236373 Method of detecting antibodies and antibody-hiv virion complexes |
| 09/29/2011 | US20110236367 Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses |
| 09/29/2011 | US20110236366 Production and uses of type i ribosome inactivating proteins |
| 09/29/2011 | US20110236362 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM |
| 09/29/2011 | US20110236359 Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria |
| 09/29/2011 | US20110236351 Therapeutic Regimen Comprising PEG-Interferon, Ribavirin and VX-950 for the Treatment of Hepatitis |
| 09/29/2011 | US20110236349 Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection |
| 09/29/2011 | US20110236348 Modulators of toll-like receptor 7 |
| 09/29/2011 | US20110236347 Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection |
| 09/29/2011 | US20110236344 Synthetic mimics of mammalian cell surface receptors: method and compositions |
| 09/29/2011 | US20110236325 Methods to treat or prevent a skin condition using a nell1 peptide |
| 09/29/2011 | US20110236321 Aerosol Foams Comprising Clindamycin Phosphate |
| 09/29/2011 | US20110236306 Compositions and methods for the removal of biofilms |
| 09/29/2011 | DE102010013081A1 Antimikrobielle Öl in Wasser Emulsion Antimicrobial oil in water emulsion |
| 09/29/2011 | CA2794558A1 Hiv vaccine |
| 09/29/2011 | CA2794480A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia |
| 09/29/2011 | CA2794359A1 Infectious hepatitis c virus-high producing hcv variants and use thereof |
| 09/29/2011 | CA2794145A1 Analogues for the treatment or prevention of flavivirus infections |
| 09/29/2011 | CA2793884A1 Crystalline forms of a macrolide, and uses therefor |
| 09/29/2011 | CA2793876A1 Antimicrobial compositions |
| 09/29/2011 | CA2793533A1 Polymorphic forms of st-246 and methods of preparation |
| 09/29/2011 | CA2790087A1 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-)-carvone, (+)-carvone, geraniol and a further essential oil component |
| 09/29/2011 | CA2785629A1 Compositions for topical administration |
| 09/28/2011 | EP2368989A1 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis c virus |
| 09/28/2011 | EP2368985A2 Compositions and methods for generating an immune response |
| 09/28/2011 | EP2368901A1 Peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368900A2 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 09/28/2011 | EP2368899A1 Avian influenza vaccine |
| 09/28/2011 | EP2368898A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 09/28/2011 | EP2368890A1 Hepatitis C virus inhibitors |
| 09/28/2011 | EP2368882A1 Anti-infective pyrimidines and uses thereof |
| 09/28/2011 | EP2368880A1 6-(Heterocycle-Substituted Benzyl)-4-Oxoquinoline Compound and Use of the Same as HIV Integrase Inhibitor |
| 09/28/2011 | EP2368878A1 Peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368877A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368876A1 Derivatives of aminoindanes, their preparation and their application in therapeutics |
| 09/28/2011 | EP2368576A2 Functionally reconstituted viral membranes containing adjuvant |
| 09/28/2011 | EP2368575A2 Dry formulation for transcutaneous immunization |
| 09/28/2011 | EP2368557A1 Methods of simultaneously treating ocular rosacea and acne rosacea |
| 09/28/2011 | EP2368555A1 Compositions and methods of use of phorbolesters |
| 09/28/2011 | EP2368547A1 Antiviral compositions comprising geraniol and carvone |
| 09/28/2011 | EP2367839A2 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth |
| 09/28/2011 | EP2367824A2 Anti-viral compounds |
| 09/28/2011 | EP2367823A1 Anti-viral compounds |
| 09/28/2011 | EP2367820A2 Novel antimicrobials |
| 09/28/2011 | EP2367813A1 Antiviral compounds |
| 09/28/2011 | EP2367809A1 Derivatives of ý(3-hydroxy-4 pyron-2-yl)methyl¨-amine and use thereof as anti-neoplastic drugs |
| 09/28/2011 | EP2367564A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| 09/28/2011 | EP2124976B1 Growth inhibition and elimination of methicillin-resistant staphylococcus aureus by lactic acid bacteria |
| 09/28/2011 | EP2041159B1 Macrocyclic compounds as antiviral agents |
| 09/28/2011 | EP1781600B1 Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors |
| 09/28/2011 | EP1697344B1 Hiv protease inhibiting compounds |
| 09/28/2011 | EP1508335B1 Compositions comprising a cocoa fraction for use in the treatment of periodontitis caused by bacteria belonging to genus porphyromonas, prevotella, fusobacterium or actinobacillus |
| 09/28/2011 | EP1424330B1 Activator for peroxisome proliferator-responsive receptor delta |
| 09/28/2011 | EP1322307B1 Methods for treating cell proliferative disorders and viral infections |
| 09/28/2011 | EP1263965B1 Avirulent, immunogenic flavivirus chimeras |
| 09/28/2011 | EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/28/2011 | CN201986748U 透气防护面料 Breathable protective fabrics |
| 09/28/2011 | CN1980956B Humanized antibody against S-surface antigen of hepatitis b virus |
| 09/28/2011 | CN1907350B Composition, extract thereof and its pharmaceutical use |
| 09/28/2011 | CN1665842B Human IgM antibody inducing apoptosis in HIV-infected cells and remedy for HIV-infection |
| 09/28/2011 | CN1646139B Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 09/28/2011 | CN102203268A Siderophore-mediated iron uptake in bacterial infection |
| 09/28/2011 | CN102203254A Sirna compositions and methods for potently inhibiting viral infection |
| 09/28/2011 | CN102203110A Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| 09/28/2011 | CN102203100A Cephalosporin having catechol group |
| 09/28/2011 | CN102203094A Novel nitrogenous heterocyclic compounds, preparation thereof and use thereof as antibacterial medicaments |
| 09/28/2011 | CN102203083A Compounds and compositions as kinase inhibitors |
| 09/28/2011 | CN102203063A Carbazole compounds and therapeutic uses of the compounds |
| 09/28/2011 | CN102203056A Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof |
| 09/28/2011 | CN102202736A Drug for treating infections |
| 09/28/2011 | CN102202686A Outer membrane vesicle prime - protein boost vaccine |
| 09/28/2011 | CN102202685A Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition |
| 09/28/2011 | CN102199628A Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 09/28/2011 | CN102199617A Dengue virus subunit vaccine and preparation method thereof |
| 09/28/2011 | CN102199613A High productive capacity HCV mutant of infectious HCV and application thereof |
| 09/28/2011 | CN102199612A Nucleotide sequence used in preparation of Mycobacterium smegmatis vaccine and application thereof |
| 09/28/2011 | CN102199611A Clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and nucleic acid vaccine thereof |
| 09/28/2011 | CN102199593A Method for linking sequences of interest |
| 09/28/2011 | CN102199571A Recombinant Bordetella bronchiseptica strain expressing ORF2 gene fragment of porcine circovirus type 2, vaccine and application |
| 09/28/2011 | CN102199560A Salmonellapullorum attenuated mutagenesis strain delta S6702 (RfaG) and construction method thereof |